Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response

The molecular dynamics of pancreatic ductal adenocarcinoma (PDAC) under chemotherapy remain incompletely understood. The widespread use of neoadjuvant chemotherapy (NAC) provides a unique opportunity to investigate PDAC samples post-chemotherapy. Leveraging a cohort from Fudan University Shanghai Ca...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cell reports. Medicine 2023-10, Vol.4 (10), p.101234-101234, Article 101234
Hauptverfasser:	Tang, Rong, Xu, Jin, Wang, Wei, Meng, Qingcai, Shao, Chenghao, Zhang, Yiyin, Lei, Yubin, Zhang, Zifeng, Liu, Yuan, Du, Qiong, Sun, Xiangjie, Wu, Di, Liang, Chen, Hua, Jie, Zhang, Bo, Yu, Xianjun, Shi, Si
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - genetics China Deoxycytidine - pharmacology Humans immune microenvironment neoadjuvant chemotherapy Neoadjuvant Therapy pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - metabolism tumor metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!